Post by Roche

Multiple sclerosis affects 2.9 million people worldwide, and delays in detecting disease activity can worsen long‑term disability and increase the economic burden on individuals, caregivers, and health systems. Complementing MRI with a simple blood test that reflects neuroinflammation‑related activity in adults diagnosed with RRMS can support more frequent insight into disease activity and help enable earlier, better‑informed treatment decisions. We remain committed to strengthening healthcare systems and bolstering their efforts to reduce the societal burden of neurological conditions.